Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT

Blood Adv. 2022 Sep 27;6(18):5327-5329. doi: 10.1182/bloodadvances.2022007753.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Ad26COVS1* / adverse effects
  • BNT162 Vaccine*
  • COVID-19* / prevention & control
  • Humans
  • Thrombocytopenia* / chemically induced
  • Thrombosis* / chemically induced

Substances

  • Ad26COVS1
  • BNT162 Vaccine